Incyte (NASDAQ:INCY) Insider Sells $72,565.60 in Stock

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 610 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the completion of the transaction, the insider owned 21,126 shares in the company, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Incyte Price Performance

Incyte stock opened at $119.65 on Friday. Incyte Corporation has a 12-month low of $89.25 and a 12-month high of $132.60. The stock has a market capitalization of $24.39 billion, a P/E ratio of 63.64, a P/E/G ratio of 4.36 and a beta of 0.78. The firm’s 50-day moving average is $119.62 and its two-hundred day moving average is $108.51.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The company’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.26 earnings per share. As a group, analysts forecast that Incyte Corporation will post 2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on INCY shares. Raymond James Financial set a $152.00 price target on Incyte in a report on Friday, October 16th. Wall Street Zen cut Incyte from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Citigroup restated a “buy” rating on shares of Incyte in a report on Monday, August 3rd. UBS Group set a $152.00 price objective on Incyte in a research report on Friday, October 30th. Finally, Oppenheimer set a $152.00 target price on Incyte in a research note on Tuesday, October 27th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Incyte presently has a consensus rating of “Hold” and a consensus target price of $132.86.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Institutional Investors Weigh In On Incyte

A number of institutional investors have recently bought and sold shares of INCY. Fiduciary Financial Advisors purchased a new position in Incyte during the second quarter worth approximately $26,000. Provenance Wealth Advisors LLC acquired a new position in shares of Incyte in the 3rd quarter valued at $33,000. Continuum Advisory LLC acquired a new position in shares of Incyte in the 2nd quarter valued at $36,000. Latitude Advisors LLC purchased a new stake in shares of Incyte during the 3rd quarter valued at $39,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Incyte during the 2nd quarter valued at $52,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

About Incyte

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.